New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT04762979
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a drug called alpelisib combined with standard hormone therapy for people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) whose cancer has worsened on hormone therapy alone. About 44 participants will take alpelisib daily along with either fulvestrant or an aromatase inhibitor. The goal is to see how long the cancer stays under control and whether tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.